Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis.
Biopsy
Oncocytoma
Renal
Review
Surveillance
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
30
04
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Active surveillance (AS) of biopsy-proven renal oncocytomas may reduce overtreatment. However, on biopsy, the risk of misdiagnosis owing principally to entities with peculiar hybrids and overlap morphology, and phenotypes argues for early intervention. To assess the benefit and harm of AS in biopsy-proven renal oncocytoma. A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). We systematically searched PubMed, Scopus, and Web of Science databases from September 26 up to October 2021, for studies that analyzed the outcomes of AS in patients with biopsy-proven renal oncocytoma. A total of ten studies with 633 patients met our inclusion criteria and were included for analysis. After a median follow-up of 34.5 mo (95% confidence interval [CI] 30.6-38.4), the overall definitive treatment rate from AS to definitive treatment was 17.3% ( Annual tumor growth of biopsy-proven renal oncocytoma is low. AS is oncologically safe, with favorable compliance of patients. Crossover to definitive treatment revealed a strong concordance between biopsy and final pathology. Further studies on the long-term outcomes of AS are needed. In this study, we examined the benefit and harm of active surveillance (AS) in biopsy-proven oncocytoma. Based on the available data, AS appears oncologically safe and may represent a promising alternative to immediate treatment. Patients should be included in AS decision discussions.
Identifiants
pubmed: 35633831
doi: 10.1016/j.euros.2022.04.009
pii: S2666-1683(22)00584-5
pmc: PMC9130085
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
8-15Informations de copyright
© 2022 The Author(s).
Références
Eur Urol. 2016 Mar;69(3):413-6
pubmed: 26386607
Stat Med. 2019 Mar 15;38(6):969-984
pubmed: 30460713
JAMA Surg. 2019 Mar 1;154(3):225-231
pubmed: 30516801
Urology. 2018 Feb;112:92-97
pubmed: 29030073
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Urol. 2006 Feb;175(2):425-31
pubmed: 16406965
Eur Urol. 2016 Apr;69(4):660-673
pubmed: 26323946
Clin Nucl Med. 2015 Apr;40(4):309-13
pubmed: 25608174
Abdom Radiol (NY). 2020 Oct;45(10):3193-3201
pubmed: 31664486
Urology. 2021 Oct;156:185-190
pubmed: 34087310
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cancer. 2012 Feb 15;118(4):997-1006
pubmed: 21766302
J Urol. 2018 Oct;200(4):731-736
pubmed: 29653161
J Urol. 2011 Oct;186(4):1218-22
pubmed: 21849182
Urology. 2020 Sep;143:173-180
pubmed: 32512107
BJU Int. 2012 Nov;110(10):1444-8
pubmed: 22520366
BJU Int. 2018 Jun;121(6):893-899
pubmed: 29397002
BJU Int. 2016 Oct;118 Suppl 3:30-34
pubmed: 27457972
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
J Urol. 2018 Mar;199(3):641-648
pubmed: 28951284
Urology. 2006 Oct;68(4):737-40
pubmed: 17070344
Minerva Urol Nefrol. 2020 Aug;72(4):389-407
pubmed: 32734748
Eur Urol. 2011 Jul;60(1):39-44
pubmed: 21477920
J Urol. 2016 Mar;195(3):581-6
pubmed: 26388501
BJU Int. 2017 May;119(5):661-666
pubmed: 28058773
BJU Int. 2021 Dec;128(6):722-727
pubmed: 34046981
World J Urol. 2021 Apr;39(4):1195-1201
pubmed: 32556559
Urology. 2005 Dec;66(6):1181-5
pubmed: 16360437
Hum Pathol. 2016 Sep;55:1-10
pubmed: 27085554
Eur Urol Focus. 2019 Nov;5(6):946-948
pubmed: 31351899